Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients ; volume:6 ; number:1 ; day:3 ; month:10 ; year:2018 ; pages:1-12 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (3.10.2018), 1-12, 12.2018

Creator: Zhao, Bin

Contributor: Zhao, Hong
Zhao, Jiaxin
SpringerLink (Online service)

DOI: 10.1186/s40425-018-0421-z

URN: urn:nbn:de:101:1-2018111223564316840932

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.3025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhao, Bin
Zhao, Hong
Zhao, Jiaxin
SpringerLink (Online service)

Other Objects (12)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials

Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

Related objects

Reset password